controlled-release levodopa / carbidopa — Competitive Intelligence Brief

controlled-release levodopa / carbidopa (controlled-release levodopa / carbidopa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

marketed Dopamine precursor with peripheral decarboxylase inhibitor Aromatic amino acid decarboxylase (AADC); dopamine pathway Neurology Small molecule

Target snapshot

controlled-release levodopa / carbidopa (controlled-release levodopa / carbidopa) — Pfizer. Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits its premature breakdown in the periphery, allowing more levodopa to reach the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
controlled-release levodopa / carbidopa TARGET	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa Benserazide Teva Italia	Levodopa Benserazide Teva Italia	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine)
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)
Sinemet (comparator)	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system
L-DOPA/DDCI	L-DOPA/DDCI	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopaminergic system
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)

Recent regulatory actions (last 90 days)

• 2026-04-27 — L-DOPA/DDCI · EMA · approved · EU · Bial - Portela C S.A.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class